Frontiers in Clinical Drug Research - Anti-Cancer Agents is a book series intended for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology and pharmaceutical chemistry researchers. The eighth volume of the book features reviews on these topics:<br/> <br/> <br/> <br/>- Key data management elements in clinical trials for oncological therapeutics<br/> <br/>- Prospects for therapeutic targeting of microRNAs in brain tumors<br/> <br/>- Breast cancer vaccines: current status and future approach<br/> <br/>- Desmocollin-3 and cancer<br/> <br/>- MDM2-p53 antagonists under clinical evaluation: a promising cancer targeted therapy for cancer patients harbouring wild-type tp53<br/> <br/>- Towards targeted therapy: anticancer agents targeting cell organelle mitochondria<br/> <br/>- Anticancer therapeutic strategies in gliomas: chemotherapy, immunotherapy, and molecularly targeted therapy in adults<br/> <br/> <br/> <br/>Audience: Pharmaceutical Scientists, Medicinal Chemists, Clinical Oncologists, Researchers in Pre-clinical studies and clinical trials